| Prevalence and use of clinical pathways in 23 countries–an international survey by the European Pathway Association K Vanhaecht, M Bollmann, K Bower, C Gallagher, A Gardini, J Guezo, ... Journal of Integrated Care Pathways 10 (1), 28-34, 2006 | 298 | 2006 |
| Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? G Marisi, A Cucchetti, P Ulivi, M Canale, G Cabibbo, L Solaini, FG Foschi, ... World journal of gastroenterology 24 (36), 4152, 2018 | 190 | 2018 |
| Systematic versus on-demand early palliative care: results from a multicentre, randomised clinical trial M Maltoni, E Scarpi, M Dall'Agata, V Zagonel, R Bertè, D Ferrari, ... European Journal of Cancer 65, 61-68, 2016 | 188 | 2016 |
| In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis F Fornari, D Pollutri, C Patrizi, T La Bella, S Marinelli, A Casadei Gardini, ... Clinical cancer research 23 (14), 3953-3965, 2017 | 168 | 2017 |
| Systematic versus on-demand early palliative care: a randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life M Maltoni, E Scarpi, M Dall’Agata, S Schiavon, C Biasini, C Codecà, ... European Journal of Cancer 69, 110-118, 2016 | 165 | 2016 |
| BRAF-mutated colorectal cancer: clinical and molecular insights F Caputo, C Santini, C Bardasi, K Cerma, A Casadei-Gardini, ... International journal of molecular sciences 20 (21), 5369, 2019 | 153 | 2019 |
| Aberrant metabolism in hepatocellular carcinoma provides diagnostic and therapeutic opportunities S De Matteis, A Ragusa, G Marisi, S De Domenico, A Casadei Gardini, ... Oxidative medicine and cellular longevity 2018 (1), 7512159, 2018 | 146 | 2018 |
| Patients with advanced hepatocellular carcinoma need a personalized management: a lesson from clinical practice EG Giannini, L Bucci, F Garuti, M Brunacci, B Lenzi, M Valente, E Caturelli, ... Hepatology 67 (5), 1784-1796, 2018 | 126 | 2018 |
| Immunotherapy for colorectal cancer: where are we heading? D Basile, SK Garattini, M Bonotto, E Ongaro, M Casagrande, M Cattaneo, ... Expert opinion on biological therapy 17 (6), 709-721, 2017 | 111 | 2017 |
| Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib AC Gardini, E Scarpi, L Faloppi, M Scartozzi, N Silvestris, D Santini, ... Oncotarget 7 (41), 67142, 2016 | 103 | 2016 |
| Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis M Rimini, L Rimassa, K Ueshima, V Burgio, S Shigeo, T Tada, G Suda, ... ESMO open 7 (6), 100591, 2022 | 102 | 2022 |
| Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale AC Gardini, L Faloppi, S De Matteis, FG Foschi, N Silvestris, F Tovoli, ... European Journal of Cancer 86, 106-114, 2017 | 100 | 2017 |
| Shifts of faecal microbiota during sporadic colorectal carcinogenesis G Mori, S Rampelli, BS Orena, C Rengucci, G De Maio, G Barbieri, ... Scientific reports 8 (1), 1-11, 2018 | 98 | 2018 |
| Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept A Vitale, G Cabibbo, M Iavarone, L Viganò, DJ Pinato, FR Ponziani, Q Lai, ... The Lancet Oncology 24 (7), e312-e322, 2023 | 97 | 2023 |
| Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population A Casadei-Gardini, M Rimini, T Tada, G Suda, S Shimose, M Kudo, ... European Journal of Cancer 180, 9-20, 2023 | 95 | 2023 |
| Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients F Tovoli, L Ielasi, A Casadei-Gardini, A Granito, FG Foschi, G Rovesti, ... Journal of hepatology 71 (6), 1175-1183, 2019 | 79 | 2019 |
| Predictive and prognostic factors in HCC patients treated with sorafenib O Brunetti, A Gnoni, A Licchetta, V Longo, A Calabrese, A Argentiero, ... Medicina 55 (10), 707, 2019 | 79 | 2019 |
| Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib A Casadei Gardini, G Marisi, E Scarpi, M Scartozzi, L Faloppi, N Silvestris, ... Expert opinion on pharmacotherapy 16 (18), 2719-2725, 2015 | 74 | 2015 |
| Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials AC Gardini, E Tamburini, M Iñarrairaegui, GL Frassineti, B Sangro OncoTargets and therapy, 7315-7321, 2018 | 71 | 2018 |
| Conversion surgery for gastric cancer: a cohort study from a western center P Morgagni, L Solaini, M Framarini, G Vittimberga, A Gardini, D Tringali, ... International journal of surgery 53, 360-365, 2018 | 70 | 2018 |
Mario ScartozziUniversity of Cagliari, Italy確認したメール アドレス: unica.it